Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02682511 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02682511 · ClinicalTrials.gov record · last posted 2026-04-15

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

StatusActive, Not Recruiting
PhasePhase 2
Started2017-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 15, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

Amendment record 24 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 24 times since 2016-02-10; most recent amendment 2026-04-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-07-07
Status change Recruiting→Active, Not Recruitingv23
2016-12-06
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT02682511
Lead Sponsor Cumberland Pharmaceuticals
Conditions Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Enrollment 34 participants
Start Date 2017-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-15